Global Cancer Technology Successfully Concludes Glioblastoma Pre-Clinical Animal Studies with Impressive Results
Global Cancer Technology, a San Diego, CA biotechnology company, has successfully completed animal testing with GCT.GLIO.1, a PI3K selective inhibitor that can cross the blood brain barrier and modulate immune cell function. The company will advance the compound to Phase 1 clinical trials as a next step. - July 08, 2022
Biopharma Industry Standout Robert Proulx Joins Advisory Board of Global Cancer Technology
Global Cancer Technology is developing innovative treatments for deadly diseases like cancer, with a current focus on glioblastoma and breast cancer. To date, Mr. Robert Proulx has held numerous Board positions, is a recognized thought leader in biopharma, and currently holds dual roles as the founder and CEO of Imagion Biosystems. - May 21, 2022
A Novel Treatment Modality for COVID-19: Global Cancer Technology is Developing a Nanoparticle Which May Selectively Target, Bind and Inactivate Coronavirus Virions
Global Cancer Technology, an emerging biopharmaceutical company, is developing a novel treatment modality to selectively kill the COVID-19 virus. - December 30, 2020